Clinical Trials Directory

Trials / Completed

CompletedNCT01887275

A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B

Medical Ozone Versus Conventional Interferon-α Treatment of Patients With Chronic Hepatitis B -A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
439 (actual)
Sponsor
Nanfang Hospital, Southern Medical University · Academic / Other
Sex
All
Age
12 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the efficacy and safety of medical ozone in treatment of chronic hepatitis B patients.

Detailed description

Total of 439 patients with chronic hepatitis B were divided according to patients' intention into two arms. 173 patients in arm I were treated with medical ozone therapy with humares which was made in Germany for at least 12 weeks.266 patients in arm II were treated with conventional interferon-α for at least 24 weeks.Patients in both groups were followed-up for 24 weeks.Virology response, biochemistry response and hepatitis B viral serological response will be studied at 12 weeks after the treatment, at the end of treatment and after 24 weeks of follow-up.

Conditions

Interventions

TypeNameDescription
DEVICEmedical ozone therapy with humaresMedical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
DRUGconventional interferon-αPatients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.

Timeline

Start date
2010-03-01
Primary completion
2013-02-01
Completion
2013-02-01
First posted
2013-06-26
Last updated
2013-06-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01887275. Inclusion in this directory is not an endorsement.